Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 17/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27111105 | 0.85 | CYP1A2 (0.50) | ENPP1CYP1A2CYP2D6SUV39H1PRMT1 | |
| SCHEMBL20814047 | 0.83 | ENPP1 (0.62) | ENPP1CYP1A2CYP2D6SUV39H1PRMT1 | |
| SCHEMBL20813890 | 0.81 | ENPP1 (0.83) | ENPP1CYP1A2CYP2D6SUV39H1PRMT1 | |
| SCHEMBL20814052 | 0.80 | ENPP1 (0.66) | ENPP1CYP1A2CYP2D6SUV39H1PRMT1 | |
| SCHEMBL25841281 | 0.80 | ENPP1 (0.69) | ENPP1CYP1A2CYP2D6 | |
| SCHEMBL20814067 | 0.80 | CYP1A2 (0.76) | ENPP1CYP1A2CYP2D6 | |
| SCHEMBL20814048 | 0.80 | ENPP1 (0.68) | ENPP1CYP1A2CYP2D6SUV39H1PRMT1 | |
| SCHEMBL25841307 | 0.80 | ENPP1 (0.57) | ENPP1CYP1A2CYP2D6ENPP3 | |
| SCHEMBL31502048 | 0.78 | ENPP1 (0.66) | ENPP1CYP1A2CYP2D6SUV39H1PRMT1 | |
| SCHEMBL24015442 | 0.78 | ENPP1 (0.67) | ENPP1ENPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | STINGRAY THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4327882-A2 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| WO-2023077083-A1 | ENPP1 INHIBITORS AS INHIBITORS OF METASTASIS | ANGARUS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022125613-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | Stingray Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
| WO-2021226136-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ANGARUS THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2019051269-A1 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885CYP1A2 4507/4885CYP2D6 4382/4885 |
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | ENPP1, ENPP3, PPP1R1B | ENPP1 1/4885CYP1A2 4462/4885CYP2D6 2663/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885CYP1A2 4507/4885CYP2D6 4382/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | ENPP1 1/4885CYP1A2 4654/4885CYP2D6 4583/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885CYP1A2 4507/4885CYP2D6 4382/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885CYP1A2 4507/4885CYP2D6 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.